A 42-year-old man with a history of chronic hepatitis B, maintained on tenofovir, was evaluated for cough and shortness of breath. After initial evaluation in the outpatient setting demonstrated a large right-sided pleural effusion, he was seen at his local Emergency Department where CT and subsequent MR identified a large (22.2 cm) Liver Reporting and Data System (LI-RADS) 5 mass occupying the right hepatic lobe (Fig. 1) that exhibited arterial-phase hyperenhancement, washout, and an enhancing pseudo-capsule. An enhancing tumor thrombus was also visible within the right main portal vein. Further evaluation identified an alpha fetoprotein (AFP) of 34,000 and a history of unintentional 15 lbs weight loss over a period of months. As a result of the large mass, the patient required multiple drainages for recurrent pleural effusions. He was empirically started on anti-vascular endothelial growth factor (VEGF) therapy with lenvatinib and referred to interventional radiology for consideration of radioembolization, but this was deferred due to an elevated shunt fraction, with approximately 3.6% shunting to the lungs. The patient was then referred for consideration of resection. Other than hepatitis B, he had no other pertinent medical history.
WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.